51 citations,
June 2021 in “Signal Transduction and Targeted Therapy”
The document concludes that while there are promising methods to control CRISPR/Cas9 geneediting, more research is needed to overcome challenges related to safety and effectiveness for clinical use.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Geneediting to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
Potential treatments for hair loss, including Minoxidil, finasteride, RU58841 and various upcoming pharmaceuticals, geneediting and cloning. It is suggested that a cure, if found, would be highly profitable due to the large number of people affected by hair loss globally.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, geneediting, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of geneediting for severe genetic conditions.